Panadol Femina (Paracetamol, Hyoscine Butylbromide)

Paracetamol, the active ingredient in Panadol Femina, is an analgesic presented as a tablet for oral use. It treats mild to moderate pain and reduces fever, often combined with hyoscine butylbromide to relieve menstrual discomfort. GNH USA supplies Panadol Femina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Panadol Femina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Panadol Femina combines paracetamol and hyoscine butylbromide to address pain and smooth‑muscle spasm in the following conditions:

- Menstrual cramps: provides analgesia while reducing uterine cramping. - Dysmenorrhoea: eases pain associated with primary or secondary menstrual pain. - Mild to moderate musculoskeletal pain: offers fever reduction and pain relief when muscle spasm is present. - Headache associated with tension: alleviates tension‑type headache accompanied by mild muscular tension. - Low‑grade fever of unknown origin: helps lower body temperature while managing accompanying discomfort. - Post‑operative recovery pain: supports pain control when mild spasm‑related discomfort occurs after minor procedures.

Panadol Femina may cause adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild stomach upset may occur. - Dizziness: transient light‑headedness reported by some users. - Dry mouth: reduced salivation is occasionally noted. - Skin rash: mild erythema or itching may appear. - Constipation: occasional reduced bowel movements. - Headache: paradoxical headache can be experienced.

Serious or Rare Side Effects: - Hepatotoxicity: risk of liver injury with excessive paracetamol exposure. - Allergic reaction: hives, swelling, or anaphylaxis in sensitive individuals. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Cardiac arrhythmia: rare tachycardia linked to anticholinergic effect. - Urinary retention: difficulty voiding due to smooth‑muscle inhibition. - Vision changes: blurred vision or difficulty focusing.

When using Panadol Femina, consider the following safety measures:

- Liver health: avoid use in patients with severe hepatic impairment. - Alcohol consumption: limit alcohol intake to reduce liver risk. - Pregnancy: consult a healthcare professional before use during pregnancy. - Breastfeeding: discuss with a physician, as small amounts may pass into milk. - Drug interactions: review concomitant medications for potential additive effects. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Panadol Femina can interact with several medicines; monitoring is advised.

Major Interactions (Avoid): - Warfarin: increased bleeding risk due to enhanced anticoagulant effect. - High‑dose ibuprofen or other NSAIDs: heightened risk of liver and kidney injury. - Carbamazepine: may reduce paracetamol plasma levels, lowering efficacy.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): potential for increased bleeding. - Diuretics: may enhance anticholinergic‑related urinary retention. - Antihistamines: additive dry‑mouth and sedation effects. - Oral contraceptives: possible alteration of paracetamol metabolism.